Wang Maomao, Li Ting, Qiao Fan, Wang Laixing, Li Chunlin, Gong Yanping
Department of Neurosurgery, Chang Hai Hospital, The Second Military Medical University, Shanghai.
Huo Shen Shan Hospital, Wuhan.
Medicine (Baltimore). 2020 Sep 4;99(36):e21428. doi: 10.1097/MD.0000000000021428.
Coronavirus disease (COVID-19) is spreading worldwide. The reported possible neurological symptoms are varied and range from subtle neurologic deficits to unconsciousness. Knowledge regarding the detection, diagnosis, treatment, and follow-up of COVID-19-associated neurological damage is still limited. We report a case of serious neurological damage and mental abnormalities in a patient who was finally confirmed to have COVID-19 based on IgM and IgG antibodies in the cerebrospinal fluid (CSF).
A 68-year-old man had slight flu-like symptoms and transient loss of consciousness in early February. Exaggerated unconsciousness and deteriorating mental abnormalities occurred over the next month without severe respiratory symptoms. Craniocerebral computed tomography showed normal results, but antibodies against severe acute respiratory syndrome coronavirus 2 were 100 times higher in the CSF than in the serum; tests for viral ribonucleic acid showed negative results with both a nasopharyngeal swab and CSF sample.
COVID-19 pneumonia was diagnosed based on symptoms and positive results for IgM and IgG in the CSF.
Antiviral, fluid, and nutritional support were administered for 30 days before admission without obvious improvement. A further 18 days of routine antiviral therapy, immunoglobulin therapy (10 g per day for 5 days), and antipsychotic drug treatment were administered.
The patient's neurological and mental abnormalities were greatly ameliorated. He was discharged with mild irritability, slight shaking of the hands, and walking fatigue. These symptoms have persisted up to our last follow-up (May 4, 2020).
We believe this is the first case involving neural system injury in a patient who confirmed COVID-19 based on CSF antibody test results. Negative ribonucleic acid test results, strong positivity for antibodies, and high protein levels in the CSF suggest the possibility of autoimmune encephalitis secondary to COVID-19. This case highlights additional novel symptoms of COVID-19, and these data are important for the assessment and follow-up of COVID-19 patients.
冠状病毒病(COVID-19)正在全球范围内传播。报告的可能出现的神经症状多种多样,从轻微的神经功能缺损到昏迷不等。关于COVID-19相关神经损伤的检测、诊断、治疗及随访的知识仍然有限。我们报告了一例最终根据脑脊液(CSF)中的IgM和IgG抗体确诊为COVID-19的患者出现严重神经损伤和精神异常的病例。
一名68岁男性在2月初出现轻微流感样症状和短暂意识丧失。在接下来的一个月里,意识障碍加重且精神异常恶化,但无严重呼吸道症状。颅脑计算机断层扫描结果正常,但脑脊液中严重急性呼吸综合征冠状病毒2抗体水平比血清中高100倍;病毒核糖核酸检测显示鼻咽拭子和脑脊液样本结果均为阴性。
根据症状及脑脊液中IgM和IgG阳性结果诊断为COVID-19肺炎。
入院前给予30天的抗病毒、补液及营养支持治疗,无明显改善。随后又进行了18天的常规抗病毒治疗、免疫球蛋白治疗(每天10g,共5天)及抗精神病药物治疗。
患者的神经和精神异常得到明显改善。出院时仍有轻度易怒、双手轻微震颤及行走疲劳。这些症状一直持续到我们最后一次随访(2020年5月4日)。
我们认为这是首例基于脑脊液抗体检测结果确诊COVID-19的患者出现神经系统损伤的病例。核糖核酸检测结果为阴性、抗体强阳性及脑脊液中蛋白水平升高提示可能为COVID-19继发自身免疫性脑炎。该病例突出了COVID-19的其他新症状,这些数据对于COVID-19患者的评估和随访具有重要意义。